YH25448 (Lazertinib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for YH25448 (Lazertinib), covering 2024-03-22 to 2024-03-22. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301) [Phase 3]